ArticleAmerican journal of translational research2025
Serum Homocysteine (Hcy), Cystatin C (Cys-C), and Urine Microalbumin (mAlb) are critical for early diagnosis of diabetic nephropathy.
Article in American journal of translational research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Association Between Serum Homocysteine and Chronic Kidney Disease Severity in Vietnamese Outpatients With Type 2 Diabetes: A Cross-Sectional Study.Endocrinology, diabetes & metabolism · 2026Article
- Development and validation of an early risk prediction model based on inflammatory and metabolically derived markers for early diagnosis of diabetic kidney disease.Scientific reports · 2026Article
- Potential of circulating miR-29a and miR-142-5p as biomarkers for diabetic nephropathy: a cross-sectional study.Frontiers in medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesTo evaluate the clinical value of combined serum homocysteine (Hcy), cystatin C (Cys-C), and urine microalbumin (mAlb) in early diagnosis of diabetic kidney disease (DKD).
methodsA total of 450 participants were retrospectively enrolled, including 150 DKD patients, 150 patients with type 2 diabetes mellitus (T2DM) without nephropathy, and 150 healthy controls. Serum Hcy, Cys-C, HbA1c, glucose, lipids, and urine mAlb were measured. Group differences were assessed using Kruskal-Wallis tests. Receiver operating characteristic (ROC) curves were generated to evaluate diagnostic performance. Least absolute shrinkage and selection operator (LASSO) regression and SHAP analysis were applied to identify key predictive features.
resultsDKD patients showed significantly higher Hcy (22.42±5.15 μmol/L), Cys-C (1.82±0.41 mg/L), and urine mAlb (180.41±42.81 mg/L) than T2DM patients (all P < 0.05). Combined indicators achieved a sensitivity of 82.0%, specificity of 86.7%, and an area under the ROC curve (AUC) of 0.928, outperforming single markers (P < 0.001). LASSO-SHAP analysis identified mAlb dynamics (e.g., AUC, 24-month values) as the dominant predictor.
conclusionsCombined Hcy, Cys-C, and mAlb testing improves early DKD diagnostic accuracy, enabling timely intervention. Single-center design and small sample size warrant multicenter validation.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.